FDA grants breakthrough status to sleep drug daridorexant for children and teenagers with insomnia
The FDA has granted Breakthrough Therapy Designation to daridorexant for insomnia in patients aged 10 to under 18, recognising positive Phase 2 evidence and a condition with no currently approved drug treatment for children.
The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in children and adolescents aged 10 to under 18, Swiss biotechnology company Idorsia announced on Wednesday, 4 November 2026, in a step that could speed up the development of a treatment for a condition that currently has no approved drug option for young patients in the United States.
The designation recognises both the preliminary clinical evidence behind the drug and the significant unmet medical need in paediatric insomnia. Idorsia said no pharmacological treatment is currently approved by the FDA for insomnia disorder in paediatric patients, leaving families and clinicians to rely on behavioural approaches and on medicines used outside their licensed indications.
Daridorexant is a next-generation dual orexin receptor antagonist, a class of medicine that works by selectively reducing wake drive rather than broadly suppressing brain activity. Idorsia says the drug was designed with a pharmacokinetic profile intended to provide efficacy through the night while minimising residual effects the following morning, a balance that matters particularly for school-age children and teenagers.
The evidence behind the designation comes from a large Phase 2 study, registered as NCT05423717, which was a multicentre, randomised, double-blind, placebo-controlled dose-finding trial. It enrolled 165 children and adolescents aged 10 to under 18 with insomnia disorder, who received daridorexant at 10, 25 or 50 milligrams, or a placebo, over two weeks.
According to Idorsia, the study demonstrated a statistically significant, dose-dependent improvement in total sleep time across the overall paediatric population, with pronounced efficacy in patients with neurodevelopmental disorders, a group in which sleep problems are often more severe and harder to treat. The full dataset from the trial is currently under evaluation by a high-impact scientific journal, the company said.
Breakthrough Therapy Designation is not an approval. It is a regulatory status given to drugs intended to treat a serious condition where preliminary clinical evidence indicates a substantial improvement on a clinically significant endpoint, together with available safety data. In practice, it provides for intensive FDA guidance and closer collaboration between the regulator and the developer as the programme moves forward.
That distinction matters for families reading Wednesday's announcement. Daridorexant for paediatric use remains investigational and is not approved or marketed for children or adolescents in any country, Idorsia stressed. The designation shortens the regulatory conversation; it does not put the medicine in pharmacies or establish its long-term safety in young patients.
What happens next is a new development programme. Idorsia said it expects to initiate the new programme in the second half of next year, building on the Phase 2 dose-finding results to test the drug in larger groups over longer periods. Those later trials will need to confirm not only that children sleep longer, but that the benefit is sustained, that daytime functioning improves, and that side effects remain acceptable.
The announcement also highlights a wider gap in children's medicine. Insomnia in childhood and adolescence is linked to difficulties with learning, mood and behaviour, and to strain on whole families, yet drug development for sleep disorders has historically focused on adults. Adult studies of daridorexant, published in The Lancet Neurology, showed significant improvements in sleep onset, sleep maintenance and self-reported total sleep time at 25 and 50 milligram doses compared with placebo, but adult results cannot simply be assumed to apply to younger patients.
For now, the FDA's decision puts paediatric insomnia on a faster regulatory track and gives Idorsia a clearer path to larger trials. Whether daridorexant ultimately becomes the first FDA-approved pharmacological treatment for insomnia in 10- to 17-year-olds will depend on the evidence those trials produce, and on a safety profile that can stand up to the scrutiny that any medicine for children must face.
More in Health & Science
Photo: A blood pressure measurement being taken (file image)
Health & ScienceSmall Surrey trial finds supplement improved blood-vessel health markers, but researchers stress it is not proof against disease
A six-month randomised trial at the University of Surrey found that adults taking a multi-ingredient supplement showed better blood-vessel function, arterial flexibility and systolic blood pressure than a placebo group, though the study did not test clinical outcomes.
Photo: Blood samples being tested in a laboratory (file image)
Health & ScienceMulti-cancer blood tests to be offered at about 200 GP surgeries in England in major new trial
More than 20,000 patients aged 45 and over with abdominal symptoms will be offered blood tests designed to detect 13 cancers sooner, under a government-funded trial led by the University of Birmingham.
Photo: Laboratory test tubes, of the kind used to analyse blood samples in studies of diet and metabolism (file image)
Health & ScienceBlood signatures may explain about half of ultra-processed food’s link to heart disease and diabetes, study finds
Researchers at UCL and Imperial College London have identified blood molecule patterns for ultra-processed and minimally processed diets that may explain roughly half of the link between such diets and later heart disease and type 2 diabetes.